{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-080473","form_type":"8-K","ticker":"RZLT","cik":"0001509261","company_name":"Rezolute, Inc.","filed_at":"2025-08-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.168896+00:00","generated_at":"2026-05-17T11:08:38.127542+00:00","sec_items":["1.01","5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Rezolute appoints Sunil Karnawat as CCO; grants 275K inducement options","bullets":["Sunil Karnawat appointed Chief Commercial Officer effective Aug 18, 2025; brings 25+ years experience including four ultra-rare disease launches at Ultragenyx.","Employment agreement: base salary $475K, annual target bonus 40%, signing bonus $65K, plus 270K stock options and 25K RSUs vesting over time.","Inducement grant of 275K stock options at $6.55/share (closing price Aug 18); vesting: 25% on first anniversary, then 36 monthly installments, accelerated upon change of control.","Karnawat will lead launch strategy and global market readiness for ersodetug, a Phase 3 therapy for congenital and tumor hyperinsulinism."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-080473","json":"https://secwatch.observer/filing/0001104659-25-080473.json","markdown":"https://secwatch.observer/filing/0001104659-25-080473.md","text":"https://secwatch.observer/filing/0001104659-25-080473.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509261/000110465925080473/0001104659-25-080473-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509261/000110465925080473/tm2523938d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T11:08:38.127542+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}